Atty. Docket No. 98,736

Serial No. 09/218,913

#4

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: Roderick L. Hall, et al.

Filing Date: December 22, 1998

Group: To be assigned

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	<u>Translation</u> Yes No
he	1	EP 0 439 442 B1	03/06/96	EPO	Printerior and printer		
W	2	WO 93/14120	07/22/93	PCT			
110	3	WO 96/03503	02/26/97	PCT		-	
Ne	4	WO 95/18830	07/13/95	PCT			
We	5 .	WO 96/35788	11/14/96	PCT			
ve	6	WO 98/33920	08/06/98	PCT			

U.S. PATENT DOCUMENTS

			0.5.	PATENT DOCUMENTS			
Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
Ne	7	5,106,833	04/21/92	Bronze, Jr. et al.	514	17	
NC	8	5,223,482	07/29/93	Schilling, Jr. et al.	514	12	
18	9	5,312,736	05/17/94	Rasmussen, et al.	435	69.7	
Nie	10	5,403,484	04/04/95	Ladner, et al.	435-	235.1	
we	11	5,436,153	07/25/95	Sprecher, et al.	435	6	
10	12	5,441,931	08/08/95	Sprecher, et al.	514	7.,	
'We	13	5,541,288	07/30/96	Nakano, et al.	530	324	
110	14	5,576,294	11/19/96	Norris, et al.	514	17.	
Nie	15	5,663,143	09/02/97	Ley, et al.	5-14	17	
Me	16	5,677,146	10/14/97	Sprecher, et al.	435	69.	
AHE	17	5,728,674	03/17/98	Sprecher, et al.	514	7	
1	18	5,731,412	03/24/98	Shimomura	530	350	
1, re	19	5,736,364	04/07/98	Kelley, et al.	475-	- 69.7	
he	20	5,747,449	05/05/98	Lasters, et al.	514	12	
tre	21	5,786,328	07/28/98	Dennis, et al.	514	17	
The	22	5,795,865	08/18/98	Markland, et al.	514	12	
ire	23	5,834,244	11/10/98	Dennis, et al.	435	69.2	

OTHER DOCUMENTS - In	cluding Author,	Title, Date,	Pertinent Pages, E	tc.
-----------------------------	-----------------	--------------	--------------------	-----

			· · ·
Examiner	Nahed	Date Considered	12/13/07

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.





Form PTO-1449

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 98,736

Serial No. 09/218,913

#5

STATEMENT BY APPLICANT PE

Applicant: Roderick L. Hall, et al.

Filing Date: December 22, 1998

Group: To b e assigned

U.S. PATENT DOCUMENTS

The OTHER DOCUMENTS - Including Author, Title, Date, Pertinent Pages, Etc.

Examiner /	Document Number	Date	Name	Class	Subclass	Filing Date	

Newton, B.B. and Hall, R.L. Mucociliary clearance in the guinea-pig is increased by ouabain (i.v.) and by hypertonic saline (14.4%) aerosol. in Cilia, Mucus and Mucociliary Interactions. Ed. Baum, G.L., Priel, Z., Roth, Y., Liron, N., Ostfeld, E., Marcel Dekker. New York. 1998. Wills, P.J., Garcia Suarez, M.J., Rutman, A., Wilson, R., and Cole, P.J. The ciliary transportability of sputum is slow on the mucus-depleted bovine trachea. American Journal of Respiratory & Critical Care Medicine 151(4):1255-1258, 1995. Wills, P.J., Hall, R.L., Chan, W.M., and Cole, P.J. Sodium chloride increases the ciliary transportability of cystic fibrosis and bronchiectasis sputum on the mucus-depleted bovine trachea. Journal of Clinical Investigation 97(11):9-13, 1997. Mathews, L.W., Spector, S., Lemm, J., and Potter, J.L. Studies on Pulmonary secretions. I. The Overall Chemical Composition of Pulmonary Secretions from Patients with Cystic Fibrosis, Bronchiectasis, and Laryngectomy. American Review of Respiratory Disease 88:199-204, 1963. Potter, J.L., Matthews, L.W., Spector, S., and Lemm, J. Studies on pulmonary secretions. II. Osmolality and the ionic environment of pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy. American Review of Respiratory Disease 67(1):83-87, 1967. Tomkiewicz, R.P., App, E.M., Zayas, J.G., Ramirez, O., Church, N., Boucher, R.C., Knowles, M.R., and King, M. Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum. American Review of Respiratory Disease 148(4 Pt 1):1002-1007, 1993. Robinson, M., Hemming, A.L., Regnis, J.A., Wong, A.G., Bailey, D.L., Bautovich, G.J., King, M., and Bye, P.T.P. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 52(10):900-903, App, E.M., King, M., Helfesrieder, R., Kohler, D., and Matthys, H. (1990) Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. American Review of Respiratory Disease 141, 605-612. Newton, B.B., Poll. C.T. and Hall, R.L. Inhalation of amiloride increases tracheal mucus velocity and decreases tracheal potential difference in the guinea-pig. Pediatric Pulmonology S17, Abs 364, 1998. McAulay, A.E., Crossley, J., Place, G.A. and Poll, C.T. Effect of UTP on ion transport in tertiary cultures of human bronchial epithelial (HBE) cells. Pediatric Pulmonology S 17, Abs 141, 1998. Vallet, V., Chraibi, A., Gaeggeler, H.P., Horisberger, J.D., and Rossier, B.C. An epithelial serine protease activates the amiloride-sensitive sodium channel. Nature 389(6651):607-610, 1997.

Notreel 12/13/02

1 12	Chraibi, A., Vallet, V., Firse, D., Hess, S.K., and Horisberger, J.D. Protease modulation of the activity of the epithelial sodium channel expressed in xenopus oocytes. <i>Journal of General Physiology</i> 111(1): 127-13 8, 1998.
Ne 13	Delaria, K.A., Muller, D.K., Marlor, C.W., Brown, J.E., Das, R.C., Roczniak, S.O. and Tamburini, P.P. Characterization of placental bikunin, a novel serine protease inhibitor. <i>Journal of Biological Chemistry</i> 272(18):12209-12214, 1997.
W 24	Marlor, C.W., Delaria, K.A., Davis, G., Muller, D.K., Greve, J.M., and Tamburini, P.P. Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two kunitz domains. <i>Journal of Biological Chemistry</i> 272(18):12202-12208, 1997.
M 215/	O'Riordan, T.G., Otero, R., Mao, Y.M., Lauredo, I., and Abraham, W.M. Elastase contributes to antigen-induced mucociliary dysfunction in ovine airways. <i>American Journal of Respiratory & Critical Care Medicine</i> 97(5):1522-1528, 1997.
NC 16,	O'Riordan, T.G., Mao, Y.M., Otero, R., Lopez, J., Sabater, J.R., and Abraham, W.M. Budesonide affects allergic mucociliary dysfunction. <i>Journal of Applied Physiology</i> 85(3):1086-1091, 1998.

Examiner

JAN 2 5 1999 8 Date Considered 12/13/02

EXAMINER: Initial if citation considered, whether of not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with any communication.

411	1		
#16 Sheet	1	of	1

	War Yak. /		
Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.
INF STA	ORMATION DISCLOSURE PE	98,736	09/218,913
	JAN 0 3 2001 H	Applicant: Roderick Hall, et al.	
	REPERTY OF THE PROPERTY OF THE	Filing Date: December 22, 1998	Group: 1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date
he	1.	5,854,396	12/29/98	Shimomura, et al.	530	350	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
Me	2.	WO 92/15605	9/17/92	PCT			Х
N	-3.	WO 97/33996	9/18/97	PCT			X
ve	4.	0 563 389	10/6/93	EPO		-	X

5. Lindberg, S., et al. (1991) "Tissue kallikrein stimulates mucociliary activity in the rabbit maxillary sinus." Acta Oto-Laryngologica 111 (6) 1126-32.

Newton, et al., "Mucociliary Clearance in the Guinea Pig is Increased by Ouabain (i.v.) and by Hypertonic Saline (14.4%) Acrosol," Cilia, Mucus, and Mucociliary Interations, United Kingdom.

Rasche B., et al. (1975) "Uber die Wirkung des Proteaseinhibitors Aprotinin auf die Lungenfunktion sowie die inhibitorische Aktivitat des Sputums bei Patienten mit chronisch-obstruktiver Bronchitis" Arzneimittel-Forschung 25 (1) 110-116, Germany.

8. Schmidt, O. P. (1977) "Drug therapy in cases of bronchosecretory disorders," MEDIKAMENTOSE THERAPIE BRONCHOSEKRETORISCHER STORUNGEN." Medizinische Klinik 72 (5) 145-160, Germany.

12/13/0	Examiner	Whed	Date Considered	12/13/02
---------	----------	------	-----------------	----------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if t in conformance and not considered. Include copy of this form with any communication.